Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir
- 4 July 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 52 (11), 981-994
- https://doi.org/10.1007/s40262-013-0093-2
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With RifabutinJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialThe Lancet Infectious Diseases, 2012
- Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing RaltegravirThe Journal of Infectious Diseases, 2011
- Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next‐generation HIV integrase inhibitor, S/GSK1349572British Journal of Clinical Pharmacology, 2011
- Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteersJournal of Antimicrobial Chemotherapy, 2011
- Methadone Induces the Expression of Hepatic Drug-Metabolizing Enzymes through the Activation of Pregnane X Receptor and Constitutive Androstane ReceptorDrug Metabolism and Disposition, 2009
- Male Genital Tract Pharmacology: Developments in Quantitative Methods to Better Understand a Complex Peripheral CompartmentClinical Pharmacology & Therapeutics, 2007
- TipranavirClinical Pharmacokinetics, 2006
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic ActivityThe Journal of pharmacology and experimental therapeutics, 2003